Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
6.23
+0.06 (0.97%)
Jun 8, 2026, 4:00 PM EDT - Market closed

Silence Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
294287325688548715
Market Cap Growth
28.73%-11.61%-52.78%25.56%-23.35%17.04%
Enterprise Value
224.33202.14177.57619.45461.96615.56
Last Close Price
6.236.086.8817.3715.2523.89
PS Ratio
350.74513.747.5121.7525.3142.60
PB Ratio
5.96-4.61-2.42-31.2920.5262.03
P/TBV Ratio
-5.96-4.61-2.37-29.2918.3961.45
P/FCF Ratio
-----96.24
P/OCF Ratio
-----77.70
EV/Sales Ratio
267.38361.614.1019.5821.3336.67
EV/FCF Ratio
-----82.86
Debt / Equity Ratio
0.000.000-0.0100
Debt / FCF Ratio
-----0.03
Net Debt / Equity Ratio
1.421.361.103.11-3.20-8.61
Net Debt / EBITDA Ratio
0.900.942.351.071.421.62
Net Debt / FCF Ratio
1.071.362.171.381.50-13.36
Asset Turnover
0.010.000.270.250.170.14
Quick Ratio
8.827.8710.274.103.965.33
Current Ratio
9.838.7211.144.624.415.69
Return on Equity (ROE)
26.78%90.27%58.08%-2302.82%-263.32%-445.64%
Return on Assets (ROA)
-63.61%-54.53%-40.07%-52.54%-47.58%-43.00%
Return on Invested Capital (ROIC)
-231.83%-253.47%-174.33%-205.38%-258.08%-147.14%
Return on Capital Employed (ROCE)
-70.48%-59.99%-44.76%-64.18%-57.30%-64.48%
FCF Yield
-----1.04%
Buyback Yield / Dilution
-0.35%-2.12%-24.69%-15.21%-8.58%-8.78%
Total Shareholder Return
-0.35%-2.12%-24.69%-15.21%-8.58%-8.78%
SEC Filings: 10-K · 10-Q